Premium
Hepatotoxicity and virological breakthrough of HCV following treatment with sofosbuvir, daclatasvir, and ribavirin in patients previously treated for tuberculosis
Author(s) -
Wahid Braira
Publication year - 2019
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.25557
Subject(s) - sofosbuvir , medicine , daclatasvir , pyrazinamide , ribavirin , coinfection , virology , hepatitis c virus , tuberculosis , hepatitis c , isoniazid , simeprevir , rifampicin , drug , human immunodeficiency virus (hiv) , pharmacology , virus , pathology
The prevalence of hepatitis C virus/tuberculosis (HCV/TB) coinfection has not been estimated globally but few studies highlight the risk of hepatotoxicity following TB treatment or HCV treatment. Previously reported data highlights the risk of drug‐induced hepatotoxicity associated with three of the first‐line anti‐TB agents: rifampin, isoniazid, and pyrazinamide specifically in patients coinfected with HIV and HCV. Thus far, direct‐acting antiviral (DAA) drug‐induced hepatotoxicity has not been reported in the literature but herein, we observed an unusual case of HCV virological breakthrough and hepatoxicity during treatment with DAA drugs in a patient who has previously been successfully treated for TB.